OBJECTIVES: We aimed to appraise the early and long-term outcome after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in patients with unprotected left main disease (ULM) and left ventricular systolic dysfunction (LVD). BACKGROUND: PCI with DES has being performed with increasing frequency in subjects with ULM and LVD, but few specific data are available. SETTING AND PATIENTS: We identified patients undergoing PCI with DES for ULM at our Center and distinguished those with ejection fraction (EF) >50% from those with 40% <EF <or=50% and those with EF <or=40%. The primary end-point was the rate of major adverse cerebro-cardiovascular events (MACCE, ie death, myocardial infarction [MI], stroke, repeat PCI or bypass surgery). RESULTS: A total of 197 patients were included, 57.4% with EF >50%, 32.0% with 40% <EF <or=50%, and 10.6% with EF <or=40%. In-hospital mortality was significantly higher in those with EF <or=40% (9.5% vs. 0 and 3.2%, P < 0.001). A total of 96% patients were followed for 23 +/- 14 months, yielding a MACCE rate of 44.2% (41.6% in those with EF >50%, 41.6% in those with 40% <EF <or=50%, and 61.9% in those with EF <or=40%, P = 0.4). Specifically, death occurred in 2.7%, 7.9%, and 28.6% (P < 0.001), cardiac death in 1.8%, 4.8%, and 23.8% (P = 0.001), MI in 8.0%, 7.9% and 0 (P = 0.4), and TVR in 15.9%, 11.1% and 33.3% (P = 0.6). CONCLUSION: Systolic ventricular dysfunction is highly correlated with in-hospital and long term death rates in patients undergoing PCI with DES for ULM disease. However it does not confer an increased risk of nonfatal adverse events or stent thrombosis.
OBJECTIVES: We aimed to appraise the early and long-term outcome after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) in patients with unprotected left main disease (ULM) and left ventricular systolic dysfunction (LVD). BACKGROUND: PCI with DES has being performed with increasing frequency in subjects with ULM and LVD, but few specific data are available. SETTING AND PATIENTS: We identified patients undergoing PCI with DES for ULM at our Center and distinguished those with ejection fraction (EF) >50% from those with 40% <EF <or=50% and those with EF <or=40%. The primary end-point was the rate of major adverse cerebro-cardiovascular events (MACCE, ie death, myocardial infarction [MI], stroke, repeat PCI or bypass surgery). RESULTS: A total of 197 patients were included, 57.4% with EF >50%, 32.0% with 40% <EF <or=50%, and 10.6% with EF <or=40%. In-hospital mortality was significantly higher in those with EF <or=40% (9.5% vs. 0 and 3.2%, P < 0.001). A total of 96% patients were followed for 23 +/- 14 months, yielding a MACCE rate of 44.2% (41.6% in those with EF >50%, 41.6% in those with 40% <EF <or=50%, and 61.9% in those with EF <or=40%, P = 0.4). Specifically, death occurred in 2.7%, 7.9%, and 28.6% (P < 0.001), cardiac death in 1.8%, 4.8%, and 23.8% (P = 0.001), MI in 8.0%, 7.9% and 0 (P = 0.4), and TVR in 15.9%, 11.1% and 33.3% (P = 0.6). CONCLUSION: Systolic ventricular dysfunction is highly correlated with in-hospital and long term death rates in patients undergoing PCI with DES for ULM disease. However it does not confer an increased risk of nonfatal adverse events or stent thrombosis.